The U.S. Food and Drug Administration (FDA) approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to treat cystic fibrosis (CF) in people ages 12 years and older who have two copies of the F508del mutation or one mutation that is responsive to SYMDEKO. SYMDEKO is Vertex’s third CF medicine and offers an important option for many patients, including those eligible who may be interested in a different treatment.

Read the full press release here.

 

SOURCE: VERTEX

« Previous Page